Last update 01 Nov 2024

NKp46 x CD16a x IL-2 x CD20

Basic Info

Related Targets
NKp46CD16aIL-2[+1]

Related

1
Drugs associated with NKp46 x CD16a x IL-2 x CD20
IPH-6501
Target
CD16a x CD20 x IL-2 x NKp46
Mechanism
CD16a modulators [+3]
Active Org.
Innate Pharma SAInnate Pharma SA
Originator Org.
Innate Pharma SAInnate Pharma SA
Active Indication
B-Cell Lymphoma [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with NKp46 x CD16a x IL-2 x CD20
NCT06088654 / RecruitingPhase 1/2
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
100 Clinical Results associated with NKp46 x CD16a x IL-2 x CD20
Login to view more data
100 Translational Medicine associated with NKp46 x CD16a x IL-2 x CD20
Login to view more data
0 Patents (Medical) associated with NKp46 x CD16a x IL-2 x CD20
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free